Cargando…
Pharmacology of enflicoxib, a new coxib drug: Efficacy and dose determination by clinical and pharmacokinetic‐guided approach for the treatment of osteoarthritis in dogs based on an acute arthritis induction model
Enflicoxib is a newly developed NSAID of the coxib class. The optimal therapeutic dose to be confirmed in the field studies was established using a combination of pharmacokinetic (PK) modelling and pharmacodynamic (PD) studies. First, a PK study was performed to determine the plasmatic profile of en...
Autores principales: | Cendrós, Josep‐Maria, Salichs, Marta, Encina, Gregorio, Vela, Jose Miguel, Homedes, Josep M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788976/ https://www.ncbi.nlm.nih.gov/pubmed/34854245 http://dx.doi.org/10.1002/vms3.670 |
Ejemplares similares
-
Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration
por: Homedes, Josep, et al.
Publicado: (2021) -
Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways
por: Solà, Josep, et al.
Publicado: (2021) -
Long-term safety evaluation of Daxocox(®) tablets (enflicoxib) in dogs after weekly oral administrations for seven months
por: Homedes, Josep, et al.
Publicado: (2021) -
Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib
por: Salichs, Marta, et al.
Publicado: (2022) -
Selective inhibition of cyclooxygenase‐2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood
por: Solà, Josep, et al.
Publicado: (2022)